ACC. 26 – Dr Ann Marie Navar (UT Southwestern, US) joins us to discuss an on-treatment durability analysis of enlicitide data from the CORALreef Lipids and CORALreef HeFH trials, evaluating the consistency of lipid-lowering effects in both general and familial hypercholesterolaemia populations.

Findings showed that enlicitide offered safe, durable LDL-C lowering at one year, with high self-reported levels of adherence in this patient population. 

Interview Questions: 

1. Enlicitide represents a novel mechanism for lipid lowering — can you briefly outline how it works and where it sits within the current lipid-lowering landscape?
2. What was the rationale behind this analysis?
3. What were your key findings?
4. How does enlicitide's durability profile compare with existing agents such as statins, PCSK9 inhibitors, and inclisiran?
5. What are the clinical implications of these findings for patients who struggle to achieve and maintain LDL-C targets on current therapies?
6. What are your key take-home messages for lipidologists and cardiologists, and what questions remain to be answered in the enlicitide programme?

Recorded on-site at ACC 2026, New Orleans.

For more expert insights and late-breaking science from ACC 2026, visit the Late-breaking Science Video Collection.

Editor: Jordan Rance
Videographer: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.